FDA reconsiders heart safety of common pain pills

WASHINGTON — Federal health experts are taking a second look this week at the heart safety of pain medications used by millions of Americans to treat arthritis and other everyday aches and pains.

The Food and Drug Administration holds a two-day meeting beginning Monday to examine the latest research on anti-inflammatory medicines called NSAIDS, which serve as the backbone of U.S. pain treatment.

The key question is whether naproxen — the key ingredient in Bayer’s Aleve and many other generic pain pills — carries a lower risk of heart attack and stroke than rival medications like ibuprofen, sold as Advil by Pfizer and Motrin by Johnson &Johnson, among others.

Debate about whether one drug is safer than others in the class has waged for more than a decade without a clear answer, underscoring the lingering questions that hang over even the most established medicines.

The FDA is asking its panel of medical experts to review a massive analysis published last year suggesting that naproxen does not increase the risk of heart problems as much as its peers. The finding came from Oxford University researchers who reviewed results from more than 700 NSAID studies involving roughly 350,000 patients.

On Tuesday panelists will vote on whether naproxen has a lower risk of heart problems than other NSAIDs. Panelists will also discuss whether naproxen should be relabeled based on the latest safety data. The FDA is not required to follow the group’s advice, though it often does.

If implemented, the labeling change could reshape the multibillion-dollar market for drugs used to treat muscle pain, arthritis and headaches. Last year U.S. consumers bought more than 275 million boxes of over-the-counter NSAIDs, representing $1.7 billion in sales, according to retail tracker IRI. Prescription NSAIDs brought in billions more, led by the Pfizer’s blockbuster Celebrex, with sales of $2.9 billion.

But before any changes can be made, FDA advisers must consider reams of data that are often riddled with complicating factors:

— The Oxford analysis is difficult to interpret because it combines information from hundreds of unrelated studies. While this approach is useful in getting a broad view of rare events — such as heart attacks — it is not considered the strongest form of medical evidence.

— Almost all of the data under discussion come from studies of prescription NSAID pain relievers, which are taken at higher doses and for longer periods than over-the-counter NSAIDs. But panelists will be asked to make recommendations on the use of non-prescription drugs as well.

— Panelists will also be asked to make recommendations for narrow subgroups of patients, including those with a history of heart problems.

This week’s FDA meeting is the latest chapter in an ongoing safety review that stretches back to 2004, when Merck &Co Inc. pulled its blockbuster pain reliever Vioxx off the market due to links to heart attack and stroke.

Vioxx had been heavily advertised as a new kind of NSAID that was supposed to be easier on the stomach. But its withdrawal shook the medical establishment and ushered in a new era of drug safety at the FDA.

In 2005, the agency added boxed warnings about the risk of heart attack and stroke to all prescription NSAIDS, including Celebrex and high-dose versions of ibuprofen and naproxen. Celebrex is the only drug from the same class as Vioxx that remains on the market.

The agency also beefed up labeling on lower-dose, over-the-counter NSAIDs like Aleve, Motrin and Advil. Those drugs currently warn patients to take the lowest dose possible for only a few days at a time to avoid the same risks as prescription NSAIDs.

But that advice is also getting a second look this week. A recent analysis by Danish researchers suggests heart problems can emerge with all NSAIDS after less than a week of treatment.

The FDA panel will also vote Tuesday on whether over-the-counter NSAID labeling should be changed to warn patients of the short-term risks.

Talk to us

More in Herald Business Journal

Left to right, president Bill Peterson, vice president Jamie Gamez, and executive vice president Jeff Cannon pose for a photo at Morris Magnets in Monroe, Washington, on Wednesday, Sept. 13, 2023. (Annie Barker / The Herald)
Gift and souvenir maker Morris Magnets calls Monroe home

Morris makes 30,000 items like refrigerator magnets and key chains a day out of its factory.

Scenes from the Jackson High School graduation ceremony at Angel of the Winds in Everett, Washington on Saturday, June 17, 2023. (Annie Barker / The Herald)
Angel of the Winds Arena commemorates 20 years in business

The 10,000 seat arena, community ice rink and conference center continues to draw 700,000 visitors to downtown Everett per year.

Two students walk along a path through campus Thursday, Aug. 4, 2022, at Everett Community College in Everett, Washington. The college’s youth-reengagement program has lost its funding, and around 150 students are now without the money they need to attend classes. (Ryan Berry / The Herald)
Fewer students enroll at state’s public colleges, study says

Enrollment has picked up since the pandemic, but the lag threatens the state’s quest for education equity.

Richie del Puerto watches as a student works to jump start a car during class at Sno-Isle Technical Skills Center on Tuesday, Nov. 2, 2021 in Everett. (Olivia Vanni / The Herald)
Washington’s Job Skills Program has trained employees for 40 years

Since 1983, over 75,000 workers have taken advantage of the state program.

Fluke Corp. President Jason Waxman at the Everett offices on Tuesday, May 9, 2023 in Everett, Washington. (Olivia Vanni / The Herald)
Everett’s Fluke Corp. adds solar test firm to its portfolio

The acquistion of Solmetric boosts Fluke’s solar test and measurement product line.

Yansi De La Cruz molds a cheese mixture into bone shapes at Himalayan Dog Chew on Thursday, Sept. 21, 2023 in Arlington, Washington. (Olivia Vanni / The Herald)
Give a dog a bone? How about a hard cheese chew from Arlington instead!

Launched from a kitchen table in 2003, Himalayan Pet Supply now employs 160 workers at its new Arlington factory.

Cash is used for a purchase at Molly Moon's Ice Cream in Edmonds, Washington on Wednesday, Aug. 30, 2023. (Annie Barker / The Herald)
Washington minimum wage to top $16 an hour next year

Meanwhile, some salaried workers and rideshare drivers could see their earnings rise from other state-required adjustments.

Inside the new Boeing 737 simulator at Simulation Flight in Mukilteo, Washington on Wednesday, Sept. 20, 2023. (Annie Barker / The Herald)
New Boeing 737 simulator takes ‘flight’ in Mukilteo

Pilots can test their flying skills or up their game at Simulation Flight in Mukilteo.

An Amazon worker transfers and organizes items at the new PAE2 Amazon Fulfillment Center on Thursday, Sept. 14, 2023, in Arlington, Washington. (Ryan Berry / The Herald)
Amazon cuts ribbon on colossal $355M fulfillment center in Arlington

At 2.8 million square feet, the facility is the largest of its kind in Washington. It can hold 40 million “units” of inventory.

A computer rendering of the North Creek Commerce Center industrial park in development at 18712 Bothell-Everett Highway. (Kidder Mathews)
Developer breaks ground on new Bothell industrial park

The North Creek Commerce Center on Bothell Everett Highway will provide warehouse and office space in three buildings.

Dan Bates / The Herald
Funko president, Brian Mariotti is excited about the growth that has led his company to need a 62,000 square foot facility in Lynnwood.
Photo Taken: 102312
Former Funko CEO resigns from the Everett company

Brian Mariotti resigned Sept. 1, six weeks after announcing he was taking a six-month sabbatical from the company.

Cash is used for a purchase at Molly Moon's Ice Cream in Edmonds, Washington on Wednesday, Aug. 30, 2023. (Annie Barker / The Herald)
Paper or plastic? Snohomish County may require businesses to take cash

County Council member Nate Nehring proposed an ordinance to ban cashless sales under $200. He hopes cities will follow suit.